December 21, 2017 From Clinical Lab Products: “Measurement of PD-L1 is challenging not only when tissue is lacking, but due to the inherent complexity of immunohistochemistry,” says Pritchett. “The testing approach demonstrated in this study shows promise as a method of assessing PD-L1 in plasma. A more objective measure of PD-L1 status could offer a path to better ... Read more
November 30, 2017 “Increasingly, medical oncologists work with multidisciplinary teams to diagnose and manage lung cancer cases. Interventional pulmonologists on these teams perform diagnostic workups, obtain tissue biopsies, and play a role in the timely diagnosis and staging of lung cancer (Ann Am Thorac Soc 2015;12(5):742-751). The number of molecular tests that can impact patient treatment is increasing, while ... Read more
October 23, 2017 CAP Today: “Liquid biopsy is a reality in oncology today. It’s amazing how rapidly it has become the standard of care. And I think pathology labs everywhere are trying to adapt to it and make themselves ready for this new reality.” Read the article.
October 15, 2017
“We can now identify a cancer’s mutations and respond with appropriate therapy without the issues inherent in solid tissue biopsy – not only the delays, but also the intratumoral heterogeneity that is often missed when sampling only one or a few tumor sites.” – Dr. Paul Walker Read the full story.
May 23, 2017
“The clinical course of newly diagnosed, advanced NSCLC can be rapid, with prognoses typically measured in months. Early intervention with appropriately targeted therapies can increase the overall chance of survival, and therefore speed is critical when obtaining biomarker information that might influence the design and initiation of a therapeutic strategy. However, the results from tumor ... Read more
March 14, 2017 China Television (CGTV) recently produced a story about Biodesix’s recent agreement with Bioyong to bring a version of the VeriStrat test to China. The story includes an explanation of how VeriStrat works, from Dr. Gary Pestano.
December 28, 2016 “VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.